CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

In practice

News and in-depth features about business management and career development in optics

Find out more


Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Biomarker in the eye predicts response to Lucentis

Scientists have identified a biological clue that could help clinicians identify which diabetic macular oedema patients will respond best to treatment

Walking stick

Researchers have identified a biomarker in the eye that is linked to how successfully patients respond to treatment for diabetic macular oedema.

In a study of 48 patients, scientists took fluid samples from the anterior chambers of the eye before treating patients with a ranibizumab injection (Lucentis).

They found that the biggest predictor of a successful patient outcome was high levels of the ICAM-1 molecule.

Study author, Dr Rajeev Muni, highlighted that the discovery gives clinicians a novel biomarker.

“The prospect of ongoing injections in the eye is daunting for patients. The fact that we can now measure a protein in the eye that allows us to predict which patients are less likely to respond to treatment, could lead to more personalised and tailored medicine, and fewer injections,” he observed.

The results are published in JAMA Ophthalmology.